Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
about
Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complexMolecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyReceptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cellsPharmacology and rationale for imatinib in the treatment of sclerodermaCrystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG ConformationAcadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell deathImatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cellsA Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerNew tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeuticsFear learning and extinction are linked to neuronal plasticity through Rin1 signaling.Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumorComputational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.Small gastrointestinal stromal tumor concomitant with early gastric cancer: a case report.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylatePharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis.Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case studyC-kit and PDGFRA gene mutations in triple negative breast cancer.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Simplified proteomics approach to discover protein-ligand interactions.Measurement of small molecule binding kinetics on a protein microarray by plasmonic-based electrochemical impedance imaging.Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicSunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cellsImatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal.
P2860
Q24599546-302BD33C-B27B-4BA0-972E-F40A85B6C984Q24685914-F4D8B9BA-6B61-46DA-8894-94D9CBE42A10Q26740953-B44AFFDF-2167-4B6A-814F-AA34329A1463Q26825153-5A459CB6-4976-443A-A34B-2436E9DFC683Q27652985-5774DA8C-C568-461D-AB78-CC9C6F8351D4Q28471941-CD3D726A-17C8-4405-8019-F26A6C9317A0Q28484493-577D1784-3497-403E-8F55-EE43F8794AA7Q28551341-FF7B4CDE-71B5-4D51-8D7C-3C8A630F2236Q30371980-1AE7B31D-A026-4FBB-8174-E5E07A171068Q30481604-23FA6F36-2155-4A60-980F-D1AAEC8C9068Q30485073-6BA648EB-CB07-4EBB-A6B5-B75463DDE03AQ33560776-23CA0C68-22E8-4508-A7C6-48E1703A4AB2Q33631185-0E4244B1-1C6D-4F07-A538-F50C57A884BAQ33651783-5DBC8E51-4B02-48EA-A379-319AA749C6EDQ33788518-CB5160B8-84F2-4134-8C39-A27495D7FDCAQ33807742-98239B3F-D83A-4A6F-AC8D-563F7D2DDCE8Q33866421-1EDAFDEE-2998-4184-90C1-E438A2BB44CFQ33867290-85C4652B-A2EA-4A9C-B254-63BD38538F77Q33871518-98C7B2EF-F70D-4FEC-8DD6-CAB01900EE61Q33875795-EC3C32B9-05AF-4C79-BB8E-6886002CC14CQ33906140-A24E657F-15F4-46BC-A4A1-50B9B4F04E3DQ33921067-43444E96-748E-46CF-B9DA-31F3D1555197Q33957571-9B0DE372-8CE2-48D0-9941-DAD33AB19FF3Q34029247-87C0C8D9-2987-4009-A077-1A8314CF9334Q34202396-DB5EC26B-C85C-458C-AB9E-121DFE7C7838Q34284128-3826A374-241D-4632-9BE7-EFC40AB64310Q34300380-4CCDE6BC-3E92-434B-AD97-6052F6D1DE71Q34344121-6313BC63-BCB4-4972-B8D9-2F87C9D350F8Q34443523-CA4838AF-65FD-4823-9BA4-A3FDE62ADB55Q34486028-C3EE273F-2818-426A-8BB1-70837585571BQ34518436-A4A7003A-642D-4EE1-BE53-F61E102C5A8CQ34596126-755890CE-BC7A-4E81-8AFB-F097798EC1AAQ34597216-9573FDA3-24D8-4198-AE95-2F57D0A1E3BEQ34630373-594FCAB4-A4B3-4C36-9601-AAFFFBF82721Q34656707-B105A088-116B-483F-A183-8CB75A919392Q34817365-53E1FF7D-7231-438E-9E70-5A4DB0A2FABEQ34884647-81AEF56E-258C-48AB-B9D6-693C40DC49A4Q34924495-89841C9E-6C26-41BC-A450-A6EB59E4B9F6Q35000871-82B7DB6C-0751-4010-ADD4-36A54AC7DA2AQ35012130-CDCAA840-A48F-405B-92FB-66B73004F259
P2860
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Inhibition of c-kit receptor t ...... ive tyrosine kinase inhibitor.
@en
type
label
Inhibition of c-kit receptor t ...... ive tyrosine kinase inhibitor.
@en
prefLabel
Inhibition of c-kit receptor t ...... ive tyrosine kinase inhibitor.
@en
P2093
P1433
P1476
Inhibition of c-kit receptor t ...... tive tyrosine kinase inhibitor
@en
P2093
P304
P407
P577
2000-08-01T00:00:00Z